Posted by Michael Wonder on 05 Oct 2020
ImmunoGen announces FDA breakthrough therapy designation for IMGN632 in relapsed or refractory blastic plasmacytoid dendritic cell neoplasm
5 October 2020 - ImmunoGen today announced that the U.S. FDA has granted breakthrough therapy designation for IMGN632 for the treatment of patients with relapsed or refractory blastic plasmacytoid dendritic cell neoplasm.
IMGN632 is a CD123-targeting antibody-drug conjugate in clinical development for haematological malignancies, including blastic plasmacytoid dendritic cell neoplasm, acute myeloid leukaemia and acute lymphocytic leukaemia.
